Gene transfer as an approach to treating hemophilia

Circulation Research

Volumn 88, Issue 2, 2001, Pages 137-144

  High, K A ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Factor IX; Factor VIII; Gene therapy; Hemophilia A; Hemophilia B

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; PLASMID VECTOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; VIRUS VECTOR;

CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG COST; GENE TRANSFER; HEMOPHILIA A; HEMOPHILIA B; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TARGET ORGAN; TREATMENT OUTCOME; VASCULAR ACCESS; X CHROMOSOME LINKAGE;

EID: 0035793325     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.88.2.137     Document Type: Review

References (77)

1. Haemophilia prophylaxis in young patients: A long-term follow-up
2. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism
3. Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice
4. Targeted disruption of the mouse factor VIII gene: A model for hemophilia A
5. A coagulation factor IX-deficient mouse model for human hemophilia B
6. A factor IX-deficient mouse model for hemophilia B gene therapy
7. The canine factor VIII cDNA and 5′ flanking sequence
8. Canine hemophilia B resulting from a point mutation with unusual consequences
9. A deletion mutation causes hemophilia B in Lhasa Apso dogs
10. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice
11. Positive and negative regulation of gene expression in eukaryotic cells with an inducible transcriptional regulator
12. Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts
13. A mammalian protein targeted by G1-arresting rapamycin-receptor complex
14. Why do so many haemophilia A patients develop an inhibitor?
15. Factor IX: Molecular structure, epitopes, and mutations associated with inhibitor formation
16. Immune responses in hemophilia B mice expressing a species-specific transgene
17. Gene therapy for the hemophilias
18. Update of HIV seroprevalence, seroconversion, AIDS incidence and immunologic correlates of HIV infection in patients with hemophilia A and B
19. Hepatitis B virus, hepatitis A virus and persistently elevated aminotransferases in hemophiliacs
20. Hepatitis C antibody and chronic liver disease in haemophilia
21. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients
22. Hepatitis C infection in children with hemophilia A and B
23. High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels
24. High-level hepatitis B virus replication in transgenic mice
25. Gene therapy and the germline
26. Germline alteration by gene therapy: Assessing and reducing the risks
27. An inherited limb deformity created by insertional mutagenesis in a transgenic mouse
28. In vivo gene therapy of hemophilia B: Sustained partial correction in factor IX-deficient dogs
29. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice
30. Proliferation induced by keratinocyte growth factor enhances in vivo retroviral-mediated gene transfer to mouse hepatocytes
31. Intramuscular injection of an adenoviral vector expressing hepatocyte growth factor facilitates hepatic transduction with a retroviral vector in mice
32. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
33. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector
34. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein
35. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector
36. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
37. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
38. Gene therapy vectors based on adeno-associated virus type 1
39. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors
40. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
41. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver
42. Sustained correction of canine hemophilia B by gene therapy in context of a null mutation
43. A proposed rAAV-liver directed clinical trial for hemophilia B
44. AAV-mediated expression of human factor IX in rhesus macaques
45. Immune responses to adenovirus and adeno-associated virus vectors in humans
46. Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein
47. Sustained expression of human factor VIII in mice using a parvovirus-based vector
48. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation
49. Post-translational modifications of recombinant myotube-synthesized human factor IX
50. In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs
51. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
52. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver
53. In vivo delivery and expression of physiological levels of functional human factor VIII in mice
54. Sustained expression of therapeutic levels of human factor VIII in mice
55. High-level tissue-specific expression of functional human factor VIII in mice
56. Complete short-term correction of canine hemophilia A by in vivo gene therapy
57. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy
58. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs
59. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
60. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
61. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes
62. In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes
63. Encapisidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells
64. Persistence in muscle of an adenoviral vector that lacks all viral genes
65. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene
66. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector
67. High doses of a helper-dependent adenoviral vectors yield supraphysiological levels of α-antitrypsin with negligible toxicity
68. Innate and acquired immunity to vectors
69. In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice
70. Generation and in vivo evaluation of a gutless adenoviral vector encoding human factor VIII
71. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
72. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors
73. Efficient lentiviral transduction of liver requires cell cycling in vivo
74. Pre-clinical studies of lentiviral vectors: Viral vectors for the treatment of hemophilia corporate symposium
75. A third-generation lentivirus vector with a conditional packaging system
76. Oral delivery of plasmid DNA encoding the factor IX gene